Navigation Links
Human C-reactive protein regulates myeloma tumor cell growth and survival
Date:9/10/2007

Scientists report that a protein best known as a common marker of inflammation plays a key role in the progression of human cancer. The research, published by Cell Press in the September issue of the journal Cancer Cell, implicates C-reactive protein (CRP) as a potential target for cancer treatment.

CRP is a protein that is made in the liver and secreted systemically during the process of inflammation in response to the inflammatory cytokine IL-6. The blood level of CRP is elevated in patients with infections, inflammatory diseases, some cardiovascular diseases, and malignancies including multiple myeloma (MM). Dr. Qing Yi and Dr. Jing Yang from the M.D. Anderson Cancer Center and colleagues designed a series of studies to investigate whether human CRP might influence the growth and survival of MM tumor cells.

The researchers found that addition of CRP to cell cultures at levels observed in patients with MM promoted myeloma cell proliferation and protected myeloma cells from chemotherapy-induced apoptosis and apoptosis induced by IL-6 withdrawal. The protective influence of CRP was also validated in a mouse model of myeloma.

The researchers went on to investigate the cell signaling pathways underlying CRP-mediated protection of myeloma cells. They demonstrated that CRP enhanced secretion of IL-6; binds activating Fcg receptors; activates PI3K/Akt, ERK, and NF-kB pathways; and inhibits caspase cascade activation induced by chemotherapy drugs. Further, CRP was shown to synergize with IL-6 in protecting myeloma cells from apoptosis.

These results provide strong evidence that CRP is not just a marker for MM but is a critical regulator of myeloma cell survival. CRP protects myeloma cells from apoptosis induced by chemotherapy drugs and stimulates myeloma cells to secrets more IL-6, which in turn provides additional protection to myeloma from apoptosis and stimulates liver cells to secrete more CRP. Thus, CRP could be a therapeutic target for breaking the vicious circle of myeloma to improve the therapeutic efficacy of currently available treatments, explains Dr. Yi.


'/>"/>

Contact: Nancy Wampler
nwampler@cell.com
617-386-2121
Cell Press
Source:Eurekalert

Related medicine news :

1. Human Genome Project Achieves Technological Triumph
2. First Vaccine Designed for Africa Cleared for Testing in Humans
3. Controversial deal on public access of the human genome map
4. Man against HIV – new vaccine ready for human trials
5. Scientists plan human cloning clinic in the United States
6. Human gene number increases
7. First human clone is near
8. Water regulation in humans
9. Fossil teeth and human development
10. Scientists found ancient Human Germ Killer
11. New standards for Human Research Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... Donor ... and Nevada and LABS, Inc., announced the future opening of a CLIA certified ... and serology testing used to determine the suitability of potential organ and ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... March 22, 2017 , ... Drs. Jennifer Houck, Lauren Smith, ... to accept new patients in need of skilled pediatric dentistry in Rock ... Care offers pediatric patients routine treatments, including cavities, sealants and fluoride applications, in a ...
(Date:3/22/2017)... Milford, PA (PRWEB) , ... March 22, 2017 , ... ... producers, according to a US Department of Agriculture report. While excess dairy can ... sensitivity play a role. Lactose sensitivity is the inability to properly digest lactose, a ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... financial consultations to families and business owners in the greater Hampton Roads area, ... American Cancer Society Relay For Life event. , Each year, hundreds of people ...
Breaking Medicine News(10 mins):
(Date:3/22/2017)... , 22. März 2017   ... und weltweit tätige Anbieter von Produkten und ... den Erwerb von EPL Archives Inc. bekannt, ... der Kunden im kompletten Zyklus regulierter Forschung, ... von Proben, Speicherung von Dokumenten und Zusatzdienstleistungen ...
(Date:3/22/2017)... 2017 TapImmune, Inc. (NASDAQ: ... development of innovative peptide and gene-based immunotherapeutics for ... announced that it will participate in two upcoming ... Glynn Wilson , Chairman and CEO of TapImmune, ... clinical pipeline and partnering opportunities for its proprietary ...
(Date:3/22/2017)... 22, 2017 A new independent study ... the proven ultraviolet-C (UV-C) disinfection solution of choice ... Published in the March issue ... , the peer-reviewed study of UV-C disinfection systems ... General Hospital and Rochester General Hospital. According to ...
Breaking Medicine Technology: